基于单次血清谷浓度的英夫利西单抗模型化治疗药物监测
该回顾性研究基于218例英夫利西单抗治疗患者数据,建立并验证了仅需单次浓度测量和末次输注信息的贝叶斯药代动力学与末次给药时间(TLD)模型,其中1C-TLD模型能满意预测未来英夫利西单抗浓度及长达三次就诊的稳态浓度,有助于优化常规治疗药物监测中的给药方案。
要点
- 单次英夫利西单抗浓度联合末次输注信息即可个体化预测未来浓度。
- 1C-TLD模型预测性能在外部验证队列中得到验证。
- 该模型可支持常规TDM中的英夫利西单抗剂量调整。
核心结论
- 仅用单次英夫利西单抗浓度和末次输注信息即可获得准确的个体浓度预测。
- 1C-TLD模型可能有助于优化常规治疗药物监测中的英夫利西单抗给药方案。
研究设计与样本
- 回顾性研究,基于法国Tours大学医院218例接受英夫利西单抗治疗的患者数据。
- 患者随机分为学习集(三分之二)和验证集(三分之一)。
- 构建并比较一室药代动力学模型与末次给药时间(TLD)模型,并设计仅用单次浓度测量的贝叶斯1C-PK和1C-TLD模型。
- 1C-TLD模型在两个外部验证队列中测试预测性能。
主要发现
- 药代动力学模型和TLD模型均能满意描述数据并提供准确参数估计。
- 药代动力学模型与TLD模型、贝叶斯1C-PK与1C-TLD模型对英夫利西单抗浓度的预测相当。
- 1C-TLD模型对未来英夫利西单抗浓度预测满意,且对采血后最多三次 upcoming 就诊的英夫利西单抗稳态浓度预测满意。
临床怎么用
- 临床可仅凭单次英夫利西单抗谷浓度和末次输注信息,利用1C-TLD模型预测未来浓度并辅助剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The pharmacokinetics of infliximab are highly variable and influence clinical response in chronic inflammatory diseases. The goal of this study was to build a Bayesian model allowing predictions of upcoming infliximab concentrations and dosing regimen adjustment, using only one concentration measurement and information regarding the last infliximab infusion. METHODS: This retrospective study was based on data from 218 patients treated with infliximab in Tours University Hospital who were randomly assigned to learning (two-thirds) or validation (one-third) data subsets. One-compartment pharmacokinetic and time since last dose (TLD) models were built and compared using learning and validation subsets. From these models, Bayesian pharmacokinetic and TLD models using one concentration measurement (1C-PK and 1C-TLD) were designed. The predictive performances of the 1C-TLD model were tested on two external validation cohorts. RESULTS: Pharmacokinetic and TLD models described the data satisfactorily and provided accurate parameter estimations. Comparable predictions of infliximab concentrations were obtained from pharmacokinetic versus TLD models, as well as from Bayesian 1C-PK versus 1C-TLD models. The 1C-TLD model showed satisfactory prediction of future infliximab concentrations and provided satisfactory predictions of infliximab steady-state concentration for up to three upcoming visits after a blood sample. CONCLUSIONS: Accurate individual concentration predictions can be obtained using a single infliximab concentration measurement and information regarding only the last infusion. The 1C-TLD model may help to optimize the dosing regimen of infliximab in routine therapeutic drug monitoring.
引用
- Ternant D, Passot C, Aubourg A, et al. Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. Clin Pharmacokinet. 2018. PMID: 29236229. doi:10.1007/s40262-017-0621-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。